UK Cancer-Focused Biotech Adaptimmune Eyes $150M US IPO
Venture capital-backed Adaptimmune Therapeutics Ltd., a U.K. biotech developing T-cell therapy to fight cancer, filed plans Monday to raise up to $150 million through an initial public offering to help fund...To view the full article, register now.
Already a subscriber? Click here to view full article